Candida News and Research

RSS
Fungal infections rarely develop resistance to combination drug therapy

Fungal infections rarely develop resistance to combination drug therapy

Leading microbiologist warns of killer fungi’s increasing threat

Leading microbiologist warns of killer fungi’s increasing threat

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

LSU Health New Orleans professor awarded $1.8 million grant to target intra-abdominal infections

LSU Health New Orleans professor awarded $1.8 million grant to target intra-abdominal infections

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Sleeping with dentures increases pneumonia risk in elderly

Sleeping with dentures increases pneumonia risk in elderly

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

American Biotech launches new silver hydrogel wound-dressing products

American Biotech launches new silver hydrogel wound-dressing products

Unusual kind of immune cell in tongue appears to play pivotal role in prevention of thrush

Unusual kind of immune cell in tongue appears to play pivotal role in prevention of thrush

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

Analysis of Candida glabrata fungus mutations reveals new genes that confer anti-fungal tolerance

Analysis of Candida glabrata fungus mutations reveals new genes that confer anti-fungal tolerance

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014